The University of Chicago Header Logo

Connection

Scott E. Eggener to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications Scott E. Eggener has written about Biomarkers, Tumor.
Scott E. Eggener
Connection Strength
1.992
Biomarkers, Tumor
  1. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
    View in: PubMed
    Score: 0.405
  2. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.
    View in: PubMed
    Score: 0.304
  3. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
    View in: PubMed
    Score: 0.270
  4. NMP22 and surveillance for recurrent bladder cancer. JAMA. 2006 Jul 05; 296(1):45; author reply 45-6.
    View in: PubMed
    Score: 0.159
  5. Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
    View in: PubMed
    Score: 0.134
  6. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272.
    View in: PubMed
    Score: 0.097
  7. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.
    View in: PubMed
    Score: 0.088
  8. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.
    View in: PubMed
    Score: 0.084
  9. Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55.
    View in: PubMed
    Score: 0.075
  10. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5.
    View in: PubMed
    Score: 0.055
  11. Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9.
    View in: PubMed
    Score: 0.050
  12. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28.
    View in: PubMed
    Score: 0.046
  13. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1.
    View in: PubMed
    Score: 0.043
  14. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
    View in: PubMed
    Score: 0.040
  15. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157.
    View in: PubMed
    Score: 0.038
  16. Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.
    View in: PubMed
    Score: 0.034
  17. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
    View in: PubMed
    Score: 0.028
  18. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.024
  19. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.